A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

• ✓
  Present: Registered before enrolment beganFirst posted 2024-08-20; recorded start 2024-10-07
• ✓
  Present: Has a defined primary outcomeA primary outcome measure is listed in the record
• ✓
  Present: The primary outcome states a time frameThe primary outcome measure records a time frame
• ✓
  Present: Participants are randomly assignedAllocation is recorded as randomised
• ✓
  Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
• —
  Not stated: Open label (no blinding)Masking is recorded as none (open label)
• —
  Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
• —
  Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
• —
  Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
• ✓
  Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
• ✓
  Present: Sponsor has 321 other studies in this databaseCounted from the lead sponsor named in the record (Bristol-Myers Squibb)
• ✓
  Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database

• The record lists 1 condition.
• Lead sponsor type recorded as: industry.
• Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1